ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,051.09
0.00%
US Tech 100
21,191.20
0.62%
다우존스 지수
43,828.06
-0.20%
Bitcoin
104,430.61
0.09%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 영국
  5. LSE
  6. Basilea Pharmaceutica Ag (0QNA)

  7. Basilea Pharmaceutica Ag (0QNA) 뉴스

0QNA

Basilea Pharmaceutica (0QNA)

Basilea Pharmaceutica Ag
일자:
정렬 기준:
 검색 관련기사 보기:LSE:0QNA
일자시간출처헤드라인심볼기업
2024/10/1014:15UK RegulatoryStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this yearLSE:0QNABasilea Pharmaceutica Ag
2024/10/1014:15UK RegulatoryStarke Cresemba® (Isavuconazol)-Umsätze in Asien-Pazifik und China lösen vierte Meilensteinzahlung für diese Region in diesem Jahr an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
2024/09/2414:15UK RegulatoryBasilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasisLSE:0QNABasilea Pharmaceutica Ag
2024/09/2414:15UK RegulatoryBasilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanogepix bei Candidämie und invasiver CandidiasisLSE:0QNABasilea Pharmaceutica Ag
2024/09/1914:15UK RegulatoryBasilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial fundingLSE:0QNABasilea Pharmaceutica Ag
2024/09/1914:15UK RegulatoryBasilea schliesst Vereinbarung mit BARDA zur Entwicklung neuartiger Medikamente für die Behandlung von Infektionen durch Pilze und Bakterien ab und erhält erste FörderungLSE:0QNABasilea Pharmaceutica Ag
2024/09/0614:15UK RegulatoryStrong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
2024/09/0614:15UK RegulatoryStarke Cresemba® (Isavuconazol)-Verkäufe in Europa lösen USD 25 Mio. Umsatzmeilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
2024/08/2714:15UK RegulatoryEntscheidung der Europäischen Kommission zur Zulassung von Antipilzmittel Cresemba® (Isavuconazol) bei Kindern und Verlängerung der Marktexklusivität löst CHF 10 Mio. Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
2024/08/2714:15UK RegulatoryEuropean Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
2024/08/2114:15UK RegulatoryStarke Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
2024/08/2114:15UK RegulatoryStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
2024/08/1314:15UK RegulatoryBasilea meldet starke Halbjahresergebnisse 2024 und erhöht signifikant den Ausblick für Umsatz und Gewinn für das GesamtjahrLSE:0QNABasilea Pharmaceutica Ag
2024/08/1314:15UK RegulatoryBasilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidanceLSE:0QNABasilea Pharmaceutica Ag
2024/06/2014:15UK RegulatoryBasilea verpartnert Onkologie-Wirkstoffkandidat Lisavanbulin mit Glioblastoma FoundationLSE:0QNABasilea Pharmaceutica Ag
2024/06/2014:15UK RegulatoryBasilea partners oncology drug candidate lisavanbulin with Glioblastoma FoundationLSE:0QNABasilea Pharmaceutica Ag
2024/05/1614:15UK RegulatoryStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
2024/05/1614:15UK RegulatoryStarke Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
2024/05/0314:15UK RegulatoryBasilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024LSE:0QNABasilea Pharmaceutica Ag
2024/05/0314:15UK RegulatoryBasilea berichtet über Präsentation neuer Daten zu Ceftobiprol (Zevtera®) auf dem Fachkongress ESCMID Global 2024LSE:0QNABasilea Pharmaceutica Ag
2024/04/2501:00UK RegulatoryBasilea-Aktionäre genehmigen an der Generalversammlung alle Anträge des VerwaltungsratsLSE:0QNABasilea Pharmaceutica Ag
2024/04/2501:00UK RegulatoryBasilea shareholders approve all proposals of the board of directors at the annual general meetingLSE:0QNABasilea Pharmaceutica Ag
2024/04/0914:15UK RegulatoryBasilea awarded CARB-X grant to develop recently acquired novel class of antibioticsLSE:0QNABasilea Pharmaceutica Ag
2024/04/0914:15UK RegulatoryBasilea erhält CARB-X-Förderung für die Entwicklung einer kürzlich erworbenen neuen Antibiotika-WirkstoffklasseLSE:0QNABasilea Pharmaceutica Ag
2024/04/0414:15UK RegulatoryBasilea gibt Erhalt der US-FDA-Zulassung für Antibiotikum ZEVTERA® (Ceftobiprol-Medocaril) für drei Indikationen bekanntLSE:0QNABasilea Pharmaceutica Ag
2024/04/0414:15UK RegulatoryBasilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicationsLSE:0QNABasilea Pharmaceutica Ag
2024/03/1115:15UK RegulatoryContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
2024/03/1115:15UK RegulatoryAnhaltend gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
2024/02/1315:15UK RegulatoryBasilea meldet starkes Gesamtjahr 2023 mit einer über der Guidance liegenden Profitabilität trotz substanziell erweitertem F&E-PortfolioLSE:0QNABasilea Pharmaceutica Ag
2024/02/1315:15UK RegulatoryBasilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolioLSE:0QNABasilea Pharmaceutica Ag
 검색 관련기사 보기:LSE:0QNA

최근 히스토리

BIT
UIJ307
Unicredit Bank
BIT
UB27M8
UniCredit Bank
BIT
P1IR29
BNP Paribas Issuance
AQSE
TR00.GB
Test Stocks
BIT
UC8T38
Unicredit Bank
BIT
I07360
INTESA SANPAOLO
BIT
P1GRA2
BNP Paribas Issuance
BIT
I09223
Intesa Sanpaolo
BIT
I07069
INTESA SANPAOLO
BIT
UC3JQS
Unicredit Bank
BIT
UB48KW
Unicredit Bank
BIT
UB0JNR
UniCredit Bank
BIT
UC4CTJ
Unicredit Bank
BIT
UI738B
Unicredit Bank
BIT
UV4KRD
Unicredit Bank
BIT
UB3JTY
UniCredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유